But three of those FDA employees told CNN that Elsa just makes up nonexistent studies, something commonly referred to in AI ...

There’s no questioning that AI should have governance and guardrails. As much good as it can bring, it also heightens risk.

The federal agency introduced Elsa last month, boasting about the AI tool's ability to increase efficiency at the FDA.

Insiders at the Food and Drug Administration are ringing alarm bells over the agency's use of an AI to fast-track drug ...

AI was supposed to boost drug discovery, but progress has stalled. Learn why the hype hasn’t delivered and what needs to ...

Hallucinations are a known problem with generative AI models—and Elsa is no different, according to Jeremy Walsh, the head of ...

Earlier this year, the FDA unveiled Elsa, an artificial intelligence tool that's expected to speed up the process for ...

With reports that FDA’s AI Elsa is “confidently hallucinating” studies that don’t exist, the use of AI to streamline drug ...

The Food and Drug Administration's new AI tool, Elsa, is reportedly generating false studies, raising concerns about the ...

Despite ambitions to streamline regulatory review, FDA’s Elsa platform has been prone to hallucinations, prompting internal scrutiny and questions about AI reliability and governance.

FDA officials say the assistant is flawed, just as the Trump administration stresses AI adoption in healthcare.

AI is transforming healthcare, from interpreting scans to powering early warning systems that guide diagnosis and treatment.